Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada

Objective Our objective was to estimate the cost effectiveness of ofatumumab plus chlorambucil (OChl) versus chlorambucil in patients with chronic lymphocytic leukaemia for whom fludarabine-based therapies are considered inappropriate from the perspective of the publicly funded healthcare system in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PharmacoEconomics Jg. 34; H. 1; S. 77 - 90
Hauptverfasser:	Herring, William, Pearson, Isobel, Purser, Molly, Nakhaipour, Hamid Reza, Haiderali, Amin, Wolowacz, Sorrel, Jayasundara, Kavisha
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Cham Springer International Publishing 01.01.2016 Springer Springer Nature B.V
Schlagworte:	Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - economics Antibodies, Monoclonal - therapeutic use Canada Chlorambucil Chlorambucil - adverse effects Chlorambucil - economics Chlorambucil - therapeutic use Chronic lymphocytic leukemia Clinical practice guidelines Cost analysis Cost-Benefit Analysis Costs Drug therapy Drug therapy, Combination Drug Therapy, Combination - adverse effects Drug Therapy, Combination - economics Economic aspects Health Administration Health care expenditures Health Economics Humans Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - economics Markov analysis Markov chains Medicine Medicine & Public Health Models, Economic Ofatumumab Original Research Article Patients Pharmaceuticals Pharmacoeconomics and Health Outcomes Public Health Quality of Life Research Quality-Adjusted Life Years Sensitivity analysis Studies Survival analysis Testing Canada Chlorambucil Chronic Lymphocytic Leukaemia Overall Response Rate Progressive Multifocal Leukoencephalopathy Overall Survival
ISSN:	1170-7690, 1179-2027, 1179-2027
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!